Clinical trials: Early Breast Cancer
Breast Cancer Invasive, Hormone-receptor-positive Breast Cancer
Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast Cancer
This is a multi-center, open-lable, prospective, randomized phase III clinical trial to further validate the efficacy and safety of neoadjuvant pyrotinib combined with chemotherapy in HR-positive/HER2-low (IHC 2+/FISH-negative)…
- Conditions
- Breast Cancer Invasive, Hormone-receptor-positive Breast Cancer, HER2 Low Breast Carcinoma, Early-stage Breast Cancer
- Trial name
- NCT06144944
- Testing
- Pyrotinib, epirubicin or doxorubicin, cyclophosphamide, paclitaxel, Epirubicin or doxorubicin, cyclophosphamide, paclitaxel
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Breast Cancer
Partial Breast Proton Therapy for Early Stage Breast Cancer
The purpose of this is to determine the efficacy and toxicity of proton therapy when used to deliver partial breast radiotherapy in patients with early stage breast cancer with low or intermediate risk factors.
- Trial name
- NCT01310530
- Testing
- Proton Beam Radiotherapy
- Where
- 2 sites in United States
- Volunteers
- 150 people
- Sponsor
- Loma Linda University
Breast Cancer
Evaluation of the Bexa Breast Examination
Objective: The "Bexa Breast Exam," or "BBE," for the purposes of this study is defined as the use of a Bexa device in conjunction with a portable, focused ultrasound examination to identify and further evaluate abnormal breast…
- Trial name
- BBE (NCT06643767)
- Testing
- Bexa and focus ultrasound
- Where
- United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Sure, Inc.
HER2-positive Carcinoma of Breast
Efficacy and Safety Evaluating Study of CT-P6 in Her2 Positive Early Breast Cancer
This study will determine whether CT-P6 and Herceptin are equivalent in patients with early-stage breast cancer undergoing neoadjuvant chemotherapy.
- Trial name
- NCT02162667
- Testing
- Trastuzumab
- Where
- 98 sites in Argentina, Belarus and 20 more
- Volunteers
- 562 people
- Sponsor
- Celltrion
Advanced Breast Cancer, Early Breast Cancer
A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer
The primary objective of this trial is to evaluate ovarian suppression following treatment with ZOLADEX 10.8 mg by luteinizing hormone (LH) within each cohort.
- Trial name
- NCT07310420
- Testing
- ZOLADEX
- Where
- 26 sites in United States
- Volunteers
- 176 people
- Sponsor
- TerSera Therapeutics LLC
Breast Cancer, Other Disorders of Bone Density and Structure
Impact of Chemotherapy Followed by Aromatase Inhibitors on Bone Health of Women With ER-positive Early Breast Cancer
The purpose of this study is to identify the combined impact on bone loss as well as the incidence of bone fractures in women with estrogen receptor (ER)-positive, early breast cancer treated with an aromatase inhibitor (AI)…
- Trial name
- POCHARBI (NCT01298362)
- Testing
- Aromatase Inhibitors, Chemotherapy
- Where
- Greece
- Volunteers
- 290 people
- Sponsor
- Hellenic Breast Surgeons Society
Early Stage Breast Cancer
Shaving as an Safe Alternative to Frozen Section Analysis
Evaluation of Tumor Bed Cavity Shaving as an Oncologically Safe Alternative to Frozen Section Analysis in Breast-Conserving Surgery and aim of study To assess the oncological safety and practicality of tumor bed cavity shaving…
- Trial name
- NCT07244588
- Testing
- Tumor bed cavity shaving
- Where
- Egypt
- Volunteers
- 30 people
- Sponsor
- Mark Ezzat Gerges
Breast Cancer
Serplulimab Plus Chemotherapy for Early-stage HR+/HER2- Breast Cancer
The goal of this clinical trial is to learn if serplulimab is effective in early HR+/HER2- breast cancer. It will also learn about the safety of serplulimab.
- Trial name
- NCT06394661
- Testing
- Serplulimab+NabPE
- Where
- China
- Volunteers
- 109 people
- Sponsor
- Henan Cancer Hospital
Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
Efficacy Study of Herceptin to Treat HER2-negative CTC Breast Cancer
This is a randomized phase II trial for patients with HER2 negative primary Breast Cancer (BC) who after completing (neo) adjuvant chemotherapy and surgery have detectable circulating tumour cells (CTC) in peripheral blood.
- Conditions
- Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Circulating Tumor Cells
- Trial name
- TREAT-CTC (NCT01548677)
- Testing
- trastuzumab
- Where
- 80 sites in Belgium, France and 2 more
- Volunteers
- 1,317 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Breast Cancer, Stage II Breast Cancer
Preoperative Herceptin and Navelbine for Breast Cancer
The purpose of this study is to find out what effects the preoperative combination therapy of herceptin and navelbine have on HER-2 positive breast cancer.
- Conditions
- Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer
- Trial name
- NCT00148681
- Testing
- Herceptin, Navelbine, Doxorubicin
- Where
- 3 sites in United States
- Volunteers
- 49 people
- Sponsor
- Dana-Farber Cancer Institute
Breast Cancer
An Evaluation of Stereoscopic Digital Mammography for Earlier Detection of Breast Cancer and Reduced Rate of Recall
The primary goal of this study is to compare, within a clinical screening setting, the performance of stereoscopic digital mammography with standard (non-stereo) digital mammography in the detection of abnormalities in the…
- Trial name
- NCT00208871
- Testing
- Stereoscopic Digital Mammography
- Where
- United States
- Volunteers
- 1,467 people, healthy volunteers welcome
- Sponsor
- Emory University
Breast Cancer
Six vs 12 Months of Trastuzumab With Docetaxel Following FEC as Adjuvant Treatment in N+ Breast Cancer
This trial will compare 6 versus 12 months of trastuzumab in combination with dose dense docetaxel following FE75C as adjuvant chemotherapy in women with axillary lymph node positive breast cancer overexpressing HER2
- Trial name
- NCT00615602
- Testing
- Docetaxel, Trastuzumab, Epirubicin
- Where
- 10 sites in Greece
- Volunteers
- 489 people
- Sponsor
- Hellenic Oncology Research Group
Breast Cancer
NOSTRA-Feasibility Study: A Study Looking at Ultrasound Guided Biopsies for Breast Cancer
A prospective non-randomised multi-centre feasibility study to assess if patients with residual cancer following dual-targeted neoadjuvant chemotherapy treatment for HER2-positive, ER-negative early breast cancer can be…
- Trial name
- NOSTRA (NCT04118192)
- Testing
- Tumour bed core biopsy
- Where
- 24 sites in United Kingdom
- Volunteers
- 72 people
- Sponsor
- University of Birmingham
Breast Cancer
Circulating Tumor DNA Guided Boost Therapy in Early Triple Negative Breast Patients With Residual Disease After Neoadjuvant Therapy
Early triple negative breast cancer patients who do not achieve pathologic complete response after neoadjuvant chemotherapy with or without immunotherapy have bad prognosis.
- Trial name
- NCT06992336
- Testing
- Apatinib, Camrelizumab, Capecitabine
- Where
- China
- Volunteers
- 430 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Breast Cancer, Stiffness of Hand, Not Elsewhere Classified
Acupuncture for Stiffness of Joint Related to Aromatase Inhibitors in Patients With Early-Stage Breast Cancer
RATIONALE: Acupuncture may help relieve joint stiffness related to aromatase inhibitors in patients with early-stage breast cancer.
- Trial name
- NCT05098951
- Testing
- Acupuncture
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Affiliated Hospital of Qinghai University
Tubular Breast Cancer Stage II, Tubular Breast Cancer Stage III
A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto)
Two regimen are currently considered to have highest efficacy for patients with high-risk early stage breast cancer: sequential treatment of high dose epirubicin, taxane, and cyclophosphamide concomitantly with a dual…
- Conditions
- Tubular Breast Cancer Stage II, Tubular Breast Cancer Stage III, Mucinous Breast Cancer Stage II, Breast Cancer Female NOS
- Trial name
- NCT02125344
- Testing
- non-pegylated liposomal doxorubicin, Carboplatin, Paclitaxel
- Where
- Germany
- Volunteers
- 961 people
- Sponsor
- GBG Forschungs GmbH
Female Breast Cancer
PROOFS-Registry - Premenopausal Women With Breast Cancer Optimally Treated With OFS
There is only limited data for premenopausal patients in general, as well as for differences in the use of OFS in the subgroups of pre- and perimenopausal patients, respectively.
- Trial name
- PROOFS (NCT05792150)
- Where
- 71 sites in Germany
- Volunteers
- 1,470 people
- Sponsor
- Women's Cancer Study Group GmbH
Breast Cancer
Data Collection Study of Raw Thermal Images for the Purpose of Developing a Device for Early Detection of Breast Cancer
Collection of thermal "images" of women with breast tumors in varying degrees of severity and of healthy women with no breast findings, in order to evaluate and improve Real Imaging's device ("RI4.0"), capabilities which will…
- Trial name
- NCT00821613
- Where
- 6 sites in Israel
- Volunteers
- 1,827 people, healthy volunteers welcome
- Sponsor
- Real Imaging Ltd.
Breast Cancer
Dose Dense Chemotherapy With Lipegfilgrastim Support in Early Breast Cancer
This is a prospective, non-interventional, single arm study, which is examining doxorubicin and cyclophosphamide (AC) once every 2 weeks with lipegfilgrastim support in early breast cancer.
- Trial name
- NCT02527317
- Testing
- Lipegfilgrastim
- Where
- Ireland
- Volunteers
- 40 people
- Sponsor
- Beaumont Hospital
Early-stage Breast Cancer
Evaluating Optimal Timing of Endocrine Therapy and Radiation Therapy in Early-stage Breast Cancer (REaCT-RETT)
REaCT-RETT will demonstrate the non-inferiority of concurrent compared to sequential endocrine therapy in patients receiving post-operative radiotherapy for early stage breast cancer.
- Trial name
- REaCT-RETT (NCT03948568)
- Testing
- Endocrine Therapy and Radiotherapy
- Where
- Canada
- Volunteers
- 262 people
- Sponsor
- Ottawa Hospital Research Institute